Background/purpose Social media (SM) has become an indispensable tool in healthcare, providing platforms for networking and ...

Objectives To assess for the first time a combination of new and established markers of macrovascular damage in patients with systemic lupus erythematosus (SLE) using oscillometry and greyscale/colour ...

Objective Androgen deprivation therapy (ADT) for prostate cancer (PCa) induces bone loss and increases fracture risk, yet baseline bone mineral density (BMD) assessment is rarely performed.

Previous studies of stroke in systemic lupus erythematosus (SLE) have had limited statistical power, combined stroke subtypes into composite outcomes, and lacked a reference population estimate.

Background Sacroiliac joint (SIJ) MRI is commonly used in diagnosing spondyloarthritis (SpA). Current Assessment of SpondyloArthritis International Society (ASAS) recommendations on reporting SIJ MRIs ...

Background Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric systemic lupus erythematosus (SLE). This study aimed to characterise the course of CI over a 1-year ...

Van Hoovels L, Vander Cruyssen B, Sieghart D, et al. A multicenter study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. RMD ...

Objective This multicentre randomised controlled trial aimed to compare the efficacy and safety of iguratimod (IGU) and hydroxychloroquine (HCQ) in patients with active primary Sjögren’s syndrome (pSS ...

Background Janus kinase inhibitors (JAKi), like baricitinib, are used as monotherapy (MONO) and in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients. This study aimed to ...

Objective To characterise phenotype and functional profibrotic M2 markers in circulating monocytes and cultured monocyte-derived macrophages (MDMs) from systemic sclerosis (SSc) patients (pts) with ...

Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 year. Methods ...